Glucose transporter 1 regulates the proliferation and cisplatin sensitivity of esophageal cancer.
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cisplatin
/ pharmacology
Drug Resistance, Neoplasm
/ drug effects
Esophageal Neoplasms
/ drug therapy
Esophageal Squamous Cell Carcinoma
/ drug therapy
Female
Gene Expression Regulation, Neoplastic
/ drug effects
Glucose Transporter Type 1
/ genetics
Humans
Male
Pyrazoles
/ pharmacology
Quinolines
/ pharmacology
RNA, Small Interfering
/ pharmacology
Signal Transduction
/ drug effects
BAY-876
GLUT1
GLUT1 inhibitor
PET
chemotherapy
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
13
11
2018
revised:
13
02
2019
accepted:
04
03
2019
pubmed:
13
3
2019
medline:
18
5
2019
entrez:
13
3
2019
Statut:
ppublish
Résumé
Glucose transporter 1 (GLUT1) expression is a prognostic marker for esophageal squamous cell carcinoma (ESCC). Recent work on GLUT1 and development of specific inhibitors supports the feasibility of GLUT1 inhibition as a treatment for various cancers. The anti-proliferative effects of GLUT1-specific small interfering RNA (siRNA) and a GLUT1 inhibitor were evaluated in ESCC cell lines. Expression of pro-proliferative and anti-proliferative signaling and effector molecules was examined by western blotting and quantitative RT-PCR. GLUT1 expression in pretreatment clinical biopsy samples was measured by immunohistochemistry and correlated with various clinicopathological parameters and response to chemotherapy. The reduction in standardized uptake value (SUV) of
Identifiants
pubmed: 30861255
doi: 10.1111/cas.13995
pmc: PMC6500964
doi:
Substances chimiques
BAY-876
0
Glucose Transporter Type 1
0
Pyrazoles
0
Quinolines
0
RNA, Small Interfering
0
SLC2A1 protein, human
0
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1705-1714Subventions
Organisme : Japanese Society for Gastroenterological Carcinogenesis
Organisme : Japan Society for the Promotion of Science KAKENHI
ID : 16K19942
Organisme : Japan Society for the Promotion of Science KAKENHI
ID : 26893203
Informations de copyright
© 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
J Nucl Med. 2013 Dec;54(12):2161-7
pubmed: 24221993
Cancer Res. 2014 Jan 15;74(2):575-85
pubmed: 24272485
Gastroenterology. 2016 May;150(5):1171-1182
pubmed: 26873401
Am J Pathol. 2018 Jan;188(1):72-83
pubmed: 29107073
Oncotarget. 2018 Apr 6;9(26):18518-18528
pubmed: 29719622
Science. 2009 Sep 18;325(5947):1555-9
pubmed: 19661383
Clin Cancer Res. 2014 Mar 1;20(5):1114-24
pubmed: 24423610
Gastric Cancer. 2017 Jan;20(1):83-91
pubmed: 26643879
Cancer Sci. 2019 May;110(5):1705-1714
pubmed: 30861255
Mol Cancer. 2010 Feb 09;9:33
pubmed: 20144215
PLoS One. 2012;7(10):e46591
pubmed: 23071593
Int J Cancer. 2009 Dec 15;125(12):2778-82
pubmed: 19569052
Tumour Biol. 2011 Feb;32(1):159-66
pubmed: 20845004
Oral Oncol. 2007 Sep;43(8):796-803
pubmed: 17207657
Ann Surg Oncol. 2011 Nov;18(12):3338-52
pubmed: 21537872
Oncol Lett. 2011 Jan;2(1):21-28
pubmed: 22870123
Int J Radiat Biol. 2009 Nov;85(11):963-71
pubmed: 19895273
Mol Cancer Ther. 2012 Aug;11(8):1672-82
pubmed: 22689530
ChemMedChem. 2015 Nov;10(11):1892-900
pubmed: 26332543
Clin Cancer Res. 2012 Mar 15;18(6):1696-703
pubmed: 22282467
Lancet. 2013 Feb 2;381(9864):400-12
pubmed: 23374478
Nat Cell Biol. 2012 Dec;14(12):1295-304
pubmed: 23178880
J Clin Oncol. 2003 Dec 15;21(24):4592-6
pubmed: 14673047
ChemMedChem. 2016 Oct 19;11(20):2261-2271
pubmed: 27552707
Oncogene. 2012 Apr 12;31(15):1869-83
pubmed: 21892204
Nat Rev Cancer. 2011 Jul 07;11(8):558-72
pubmed: 21734724
Int J Oncol. 2014 Oct;45(4):1345-54
pubmed: 25070157
Ann Surg Oncol. 2014 May;21(5):1756-62
pubmed: 24242681
Ann Surg Oncol. 2012 Jan;19(1):68-74
pubmed: 21879261